TATX-03 / ImmunoPrecise - LARVOL DELTA

"I’ll join in the temptation that $IPA can finally bring forth FDA approval for TATX-03 and move an asset out of Talem pipeline and into the clinic. #brokenrecord @BigRig_Trader LFG" (@CarbonLedgerCap)

FDA event

"$IPA IPA Updates on Investigational New Drug (IND) Enabling Program for PolyTope® TATX-03 https://t.co/8EhUv8PRN5" (@stock_titan)

IND

"$IPA ImmunoPrecise Antibodies and ChemPartner Biologics Announce PolyTope® TATX-03 Antibody Cocktail Manufacturing Collaboration https://t.co/rHv9RCZrPk" (@stock_titan)

ImmunoPrecise Moves SARS-CoV-2 PolyTope Cocktail Program’s Path Toward IND Filing (Businesswire) - "Completed preclinical efficacy studies for its newly optimized 4-antibody cocktail (TATX-03b), showing strong in vivo therapeutic efficacy and synergy for the treatment and protection against SARS-CoV-2 infection; The Company believes these are the first publicly reported in vivo synergistic effects of a multi-antibody (3+) combination treatmentIPA’s optimized, 4-Ab cocktail (TATX-03b) shows high levels of efficacy in treating SARS-CoV-2 in the preclinical study; Updated mutant binding data demonstrates continued in vitro resistance against novel variants of concern...Company has announced that they have sequence optimized their anti-SARS cocktail antibodies to increase expression, yield and quality outcomes of clinical products, while committing to ChemPartner Biologics (Shanghai) Co., Ltd. for the generation of cell banks in a royalty-free host cell line for subsequent use in cGMP manufacturing."

Licensing / partnership • Preclinical • Infectious Disease • Novel Coronavirus Disease